Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 3/20 | 0.37 |
| ▸ | TDO2 | P48775 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.36 |
| ▸ | XPO1 | O14980 | 1/20 | 0.34 |
| ▸ | AHR | P35869 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2310150 | 0.84 | TSHR (0.42) | RPS6KA3JAK3NFE2L2IDO1TDO2 | |
| SCHEMBL16829670 | 0.80 | NFE2L2 (0.40) | CES2RPS6KA3JAK3NFE2L2IDO1 | |
| SCHEMBL13243702 | 0.80 | NFE2L2 (0.40) | CES2RPS6KA3JAK3NFE2L2IDO1 | |
| SCHEMBL16829667 | 0.80 | NFE2L2 (0.40) | CES2RPS6KA3JAK3NFE2L2IDO1 | |
| SCHEMBL5249757 | 0.78 | CES2 (0.44) | CES2RPS6KA3JAK3NFE2L2IDO1 | |
| SCHEMBL21457919 | 0.77 | IDO1 (0.40) | CES2RPS6KA3JAK3NFE2L2IDO1 | |
| SCHEMBL15542721 | 0.77 | TSHR (0.43) | MAPT | |
| SCHEMBL543469 | 0.77 | NFE2L2 (0.59) | CES2NFE2L2MAPT | |
| SCHEMBL440959 | 0.76 | CES2 (0.58) | CES2IDO1MAPTRAPGEF4XPO1 | |
| SCHEMBL5543022 | 0.76 | CES2 (0.42) | CES2RPS6KA3JAK3NFE2L2IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106588809-B | A kind of preparation method of morpholine derivative | 江苏富泽药业有限公司 | 2018-12-25 | — | — | CN | claimed |
| CN-106588809-A | Preparation method of morpholine derivative | 江苏富泽药业有限公司 | 2017-04-26 | — | — | CN | claimed |
| US-8188290-B2 | Reacting secondary amine, carbon dioxide, triarylsilyl chloride and halogenation agent | GLAXO GROUP LIMITED (GB) | 2012-05-29 | — | — | US | claimed |
| CN-106588809-B | A kind of preparation method of morpholine derivative | 江苏富泽药业有限公司 | 2018-12-25 | — | — | CN | disclosed |
| CN-106588809-B | A kind of preparation method of morpholine derivative | 江苏富泽药业有限公司 | 2018-12-25 | — | — | CN | disclosed |
| CN-106588809-A | Preparation method of morpholine derivative | 江苏富泽药业有限公司 | 2017-04-26 | — | — | CN | disclosed |
| US-9272966-B2 | Method for preparing optically active 1-bromo-1[3,5-bis(trifluoromethyl)phenyl]ethane | KOWA COMPANY, LTD. (JP) | 2016-03-01 | — | — | US | disclosed |
| CN-104703603-A | Novel uses | NERRE THERAPEUTICS LTD | 2015-06-10 | — | — | CN | disclosed |
| US-20130190540-A1 | METHOD FOR PREPARING OPTICALLY ACTIVE 1-BROMO-1-[3,5-BIS(TRIFLUOROMETHYL)PHENYL]ETHANE | KOWA COMPANY, LTD. (JP) | 2013-07-25 | — | — | US | disclosed |
| EP-2597079-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 1-BROMO-1-[3,5-BIS(TRIFLUOROMETHYL)PHENYL]ETHANE | Kowa Company Ltd. (JP) | 2013-05-29 | — | — | EP | disclosed |
| EP-2311817-A1 | Isoxazoline Compounds and their Use in Pest Control | Sumitomo Chemical Company, Limited (JP) | 2011-04-20 | — | — | EP | disclosed |
| US-20050107609-A1 | Pyrimidine compounds and their use | SUMITOMO CHEMICAL COMPANY | 2005-05-19 | — | — | US | disclosed |
| US-6838463-B2 | Pyrimidine compounds and their use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-01-04 | — | — | US | disclosed |
| EP-1366026-B1 | PYRIMIDINE COMPOUNDS AND THEIR USE AS PESTICIDES | SUMITOMO CHEMICAL CO (JP) | 2004-12-01 | — | — | EP | disclosed |
| WO-2004091616-A1 | COMBINATIONS OF PAROXETINE AND 4- (S) - (4-ACETYL-PIPERAZIN-1-YL) -2- (R)- (4-FLUORO-2-METHYL-PHENYL -PIPERIDINE-1-CARBOXYLIC ACID [1- (R) -(3,5-BIS-TRIFLUOROMETHYL-PHENYL) -ETHYL] METHYLAMIDE FOR TREATMENT OF DEPRESSION AND / OR ANXIETY | GLAXO GROUP LIMITED (GB) | 2004-10-28 | — | — | WO | disclosed |
| US-20040077669-A1 | Pyrimidine compounds and their use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2004-04-22 | — | — | US | disclosed |
| EP-0709376-B1 | Phenylpiperidino derivatives as neurokinin antagonists | ASTRAZENECA AB (SE) | 2003-07-23 | — | — | EP | disclosed |
| US-6008223-A | ANTIINFLAMMATORY AGENTS FOR TREATING ASTHMA | ZENECA LIMITED (GB) | 1999-12-28 | — | — | US | disclosed |
| US-5731309-A | Substituted heteroalkyleneamine neurokinin antagonists | ZENECA LIMITED (GB) | 1998-03-24 | — | — | US | disclosed |
| EP-0709376-A2 | Therapeutic compounds | ZENECA LIMITED (GB) | 1996-05-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107609-A1 | Pyrimidine compounds and their use | TYMP, TYMS, UMPS | CES2 2005/4885RPS6KA3 1382/4885JAK3 2344/4885 |
| US-20130190540-A1 | METHOD FOR PREPARING OPTICALLY ACTIVE 1-BROMO-1-[3,5-BIS(TRIFLUOROMETHYL)PHENYL]ETHANE | RPP30, BRPF1, ALK | CES2 1977/4885RPS6KA3 46/4885JAK3 3124/4885 |
| US-20040077669-A1 | Pyrimidine compounds and their use | TYMP, TYMS, DPYD | CES2 1998/4885RPS6KA3 1487/4885JAK3 1989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.